Nymox Pharmaceutical (NYMX) Reports Positive Results of Safety Monitoring Committee Review of NX02-0018 Phase 3 Trial
8/22/2013 9:56:23 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HASBROUCK HEIGHTS, N.J., Aug. 22, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported favorable results from the most recent Safety Monitoring Committee periodic review of safety data for the Company's NX02-0018 clinical trial, one of the two Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The August 20, 2013 Safety Monitoring Committee meeting found no significant safety concerns to date. Both of the Company's pivotal Phase 3 trials have completed enrollment and treatment (a single intraprostatic injection of either drug or placebo) and patient evaluation is continuing at over 70 well-known urology investigative sites across the U.S.
Help employers find you! Check out all the jobs and post your resume.